INTELLIA THERAPEUTICS, INC. (NASDAQ:NTLA) Files An 8-K Entry into a Material Definitive AgreementItem 1.01. Amendment of Material Definitive Agreement.
On December 3, 2018, Intellia Therapeutics, Inc. (“Intellia” or the “Company”), entered into an Amendment (the “Amendment”) to its License and Collaboration Agreement (the “Collaboration Agreement”), dated as of December 18, 2014, with Novartis Institutes for Biomedical Research (“Novartis”).The Collaboration Agreement primarily focuses on ex vivo applications of the CRISPR/Cas9 technology to chimeric antigen receptor T cells (“CARTs”) and hematopoietic stem cells (“HSCs”).Under the Collaboration Agreement, Novartis has the exclusive right to develop all collaboration programs focused on CARTs, while both companies will develop HSC programs. The Amendment expands the scope of the existing Collaboration Agreement to include the ex vivo development of CRISPR/Cas9-based cell therapies using limbal stem cells primarily against selected gene targets by Novartis in exchange for a one-time payment to Intellia of $10.0 million.The Amendment also expands the scope of Intellia’s license to the Novartis lipid nanoparticle technology, as well as adjusts the payment mechanism for Novartis’ reimbursement of Intellia’s research and development costs to a non-adjustable $1.0 million per quarter for the remainder of the collaboration, clarifies the definition of a “Target” under the Collaboration Agreement and memorializes the organs excluded from Novartis’s in vivo Target selection.
On December 6, 2018, Intellia issued a press release, titled “Intellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional Stem Cell Population”, to announce the Amendment.The full text of Intellia’s press release regarding the Amendment is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The foregoing summary is qualified in its entirety by reference to the Amendment which the Company expects to file as an exhibit to its Annual Report on Form 10-K for the year ended December 31, 2018. The Company intends to seek confidential treatment for certain portions of the form of the Amendment.
Item 1.01. Financial Statements and Exhibits.
(d) Exhibits
EXHIBIT INDEX
3
Intellia Therapeutics, Inc. ExhibitEX-99.1 2 ntla-ex991_6.htm EX-99.1 ntla-ex991_6.htm Exhibit 99.1 Intellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional Stem Cell Population - Intellia’s Right to Use Proprietary Lipid Nanoparticle Technology Extended to All Settings - Intellia Will Receive a One-Time $10 Million Payment CAMBRIDGE,…To view the full exhibit click here
About INTELLIA THERAPEUTICS, INC. (NASDAQ:NTLA)
Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company’s sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company’s division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company’s subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.
